![Toni Weinschenk](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: - $ al 31/05/2026
Toni Weinschenk is the founder of Immatics Biotechnologies GmbH, founded in 2000, holding the title of Chief Innovation Officer since 2020.
Dr. Weinschenk is the founder of Immatics US, Inc., founded in 2015, holding the title of Chief Technology Officer since 2015.
Dr. Weinschenk currently holds the position of Chief Innovation Officer at Immatics NV since 2020.
Dr. Weinschenk earned a doctorate from Eberhard Karls Universität Tübingen.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
IMMATICS N.V. -.--% | 18/03/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| IMMATICS N.V. | Corporate Officer/Principal | 01/01/2020 |
Immatics Biotechnologies GmbH
 Immatics Biotechnologies GmbH BiotechnologyHealth Technology Operates as a bio technology company that develops and delivers T cell redirecting immunotherapies for treatment of cancer | Fundador | 01/01/2000 |
Immatics US, Inc.
 Immatics US, Inc. BiotechnologyHealth Technology Develops adoptive cell therapies for treatment of cancer | Fundador | 01/06/2015 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH BiotechnologyHealth Technology Operates as a bio technology company that develops and delivers T cell redirecting immunotherapies for treatment of cancer | Health Technology |
Eberhard Karls Universität Tübingen
 Eberhard Karls Universität Tübingen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Immatics US, Inc.
Immatics US, Inc. BiotechnologyHealth Technology Develops adoptive cell therapies for treatment of cancer | Health Technology |
Immatics NV
 Immatics NV Pharmaceuticals: MajorHealth Technology Engages in developing immunotherapies for cancer treatments | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
